Boba
Senior Member
- Messages
- 332
Are u in the U.S.? How did you get hold of Dr.L? Thanks!dr levine prescribed me this just two days ago. i’ll be starting the fenofibrate tomorrow!
Are u in the U.S.? How did you get hold of Dr.L? Thanks!dr levine prescribed me this just two days ago. i’ll be starting the fenofibrate tomorrow!
That's a nice find.Thanks- that's a great paper!
I'm going to quote an excerpt here for the benefit of others:
(spacing added for readability)
Another supplement I'm aware of which acts as a PPAR-alpha agonist is palmitoylethanolamide, which is actually an endogenous compound, and is widely available as a supplement, seeing some usage for treating pain and inflammation.
I've been taking 3-5 grams a day of DHA/EPA, from fish oil for a few years. Shortly after I started taking them, I noticed a reduction in how often I got ME/CFS flares but not PEM.
I still get PEM whenever I do to much physically but I only get flares now every 3-4 months. I think I use to get them about every month or so before I started the high dose fish oil.
The flares I get feel exactly like the flu and usually reduce me to not doing more than a very basic routine but only last about 24 hours. So to only get them every 3-4 months now is a BIG plus!
That's a nice find.
Garth Nicolson, after doing a lot of research to understand membranes and their dynamics,
https://science.sciencemag.org/content/175/4023/720
has worked to develop treatment, described in this paper:
https://www.sciencedirect.com/science/article/pii/S0005273613004070
Background
The effects of omega-3 fatty acids (FAs), such as eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, on cardiovascular outcomes are uncertain. We aimed to determine the effectiveness of omega-3 FAs on fatal and non-fatal cardiovascular outcomes and examine the potential variability in EPA vs. EPA+DHA treatment effects.
Methods
We searched EMBASE, PubMed, ClinicalTrials.gov, and Cochrane library databases through June 7, 2021. We performed a meta-analysis of 38 randomized controlled trials of omega-3 FAs, stratified by EPA monotherapy and EPA+DHA therapy. We estimated random-effects rate ratios (RRs) with (95% confidence intervals) and rated the certainty of evidence using GRADE. The key outcomes of interest were cardiovascular mortality, non-fatal cardiovascular outcomes, bleeding, and atrial fibrillation (AF). The protocol was registered in PROSPERO (CRD42021227580).
Findings
In 149,051 participants, omega-3 FA was associated with reducing cardiovascular mortality (RR, 0.93 [0.88-0.98]; p = 0.01), non-fatal myocardial infarction (MI) (RR, 0.87 [0.81–0.93]; p = 0.0001), coronary heart disease events (CHD) (RR, 0.91 [0.87–0.96]; p = 0.0002), major adverse cardiovascular events (MACE) (RR, 0.95 [0.92–0.98]; p = 0.002), and revascularization (RR, 0.91 [0.87–0.95]; p = 0.0001). The meta-analysis showed higher RR reductions with EPA monotherapy (0.82 [0.68–0.99]) than with EPA + DHA (0.94 [0.89–0.99]) for cardiovascular mortality, non-fatal MI (EPA: 0.72 [0.62–0.84]; EPA+DHA: 0.92 [0.85–1.00]), CHD events (EPA: 0.73 [0.62–0.85]; EPA+DHA: 0.94 [0.89–0.99]), as well for MACE and revascularization. Omega-3 FA increased incident AF (RR, 1.26 [1.08–1.48]). EPA monotherapy vs. control was associated with a higher risk of total bleeding (RR: 1.49 [1.20–1.84]) and AF (RR, 1.35 [1.10–1.66]).
Interpretation
Omega-3 FAs reduced cardiovascular mortality and improved cardiovascular outcomes. The cardiovascular risk reduction was more prominent with EPA monotherapy than with EPA+DHA.
For some reason, they didn't bother to compare that to the risk reduction from moderate daily exercise, which reduces the risk by 75-90%.
My experience with fish oil supplements always starts positive but turns negative after several weeks. I've tried different brands and different EPA/DHA ratios, but the result is always more fatigue after an initial improvement.
Whole, prepared fish doesn't have the same negative effects, though. I can eat salmon for 3 meals per day and never get the same negative effects.
the following explains how phospholipids (including cardiolipin which we found that ME patients have AntiCardiolipin antibodies) and mitochondrial function are tightly related
The Kennedy pathway is responsible for the biosynthesis of phosphatidylcholines (PC) and phosphatidylethanolamines (PE), the two most abundant phospholipids in mammalian cells. PC, the most abundant phospholipid in the mitochondrial membranes, is sourced from endoplasmic reticulum. PE is synthesized in mitochondria by the decarboxylation of phosphatidylserine by phosphatidylserine decarboxylase 1 (Psd1) at the inner mitochondrial membrane.
PC and PE are essential to the formation of intermediate structures in membrane fusion and fission events, for stabilizing membrane proteins into their optimal conformations, and for actin-filament disassembly in the end stage of cytokinesis. In people with ME/CFS, we found decreased levels of PC and PE and their downstream products: ceramides, sphingomyelins, lysophosphatidycholines, phospholipid ethers, prostaglandin D2 (PGD2) and prostaglandin F2α (PGF2α).
One critical functional implication of reduced levels of PC and PE is impaired oxidative phosphorylation. PC depletion specifically affects the function of inner membrane protein translocases of mitochondria, including the TIM23 complex. PE synthesis is critical for cytochrome bc1 complex III function in the mitochondrial inner membrane.
Preprotein binding to the TIM/TOM complex, which translocates proteins produced from nuclear DNA through the mitochondrial membrane for use in oxidative phosphorylation, is disturbed in PE-deficient mitochondria. Cytochrome c oxidase activity in the respiratory chain complex is also decreased with PE-deficiency. Reduced import of PE into the mitochondria results in the formation of respiration deficient cells, and in mitochondrial dysfunction.
Finally, reduced levels of lysophosphatidycholines and phospholipid ethers, as well as of PC and PE, can impede mitochondrial respiration. Reduced synthesis of PGF2α and PGD2 in phospholipase A2γ-deficient mice induces mitochondrial dysfunction as well as oxidative stress that can contribute to further mitochondrial damage.
This metabolomics paper found decreased levels of certain membrane phospholipids in ME patients compared to controls, notably phosphatidyl-choline, phosphatidyl-ethanolamine, and related plasmalogens. This confirms previous research findings of decreased membrane phospholipids.
I shop around for NT Factor powder that comes in the tub, and can usually find either Nutricologyor Allergy Research for around US$50 vs $92.NTFactor is an interesting supplement, though I think regular soy lecithin is worth trying before buying the extremely expensive NTFactor branded supplement. NT Factor claims to have a proprietary blend in certain ratios, but I suspect that's mostly marketing. Regular soy lecithin is likely very similar to the proprietary NTFactor soy lecithin extract: https://examine.com/supplements/soy-lecithin/research/#sources-and
If you have too much choline. Most ME/CFS patients tend to be short of acetylcholine.A word of caution: Cholinergic supplements are known to cause or worsen depressive symptoms. There are several reports online of NT Factor causing irritability and similar symptoms of cholinergic excess - https://forums.phoenixrising.me/threads/nt-factor-gives-irritability-anxiety-and-rage.80994/
I eat salmon about once a week, maybe twice, and my EPA and DHA are always well into the normal to high normal level. I'm usually short of the alpha linoleic acid which is in flax seeds and need to supplement thatWhole, prepared fish doesn't have the same negative effects, though. I can eat salmon for 3 meals per day and never get the same negative effects. In some studies, omega-3s from whole fish were more bioavailable than fish oil supplements, so I'm possibly consuming even more omega 3s via fish than I was via fish oil.
I can share what I have in my notes about choline, which may help:
Lecithin contains phosphatidyl-choline (PC), which is one of the three main forms of supplemental choline.
100mg PC contains 13mg choline.
The other main forms of supplemental choline are citicoline (CDP-choline) and glycero-phospho-choline (GPC).
100mg GPC contains 40mg choline.
Milk contains both PC and GPC. Both PC and GPC are naturally found in the brain.
CDP-choline is temporarily made by the body when synthesizing its own PC.
Since choline synthesis in the body consumes a large percentage of the body's methyl donors, taking supplemental choline should free up a large percentage of the body's methylation capacity.
Choline should not be taken at the same time as carnitine, as they compete with each other for transport across the blood-brain-barrier.
Phosphatidyl choline is only one of the phospholipids needed in mitochondrial membranes. There are others which are important, too, and there needs to be a balance between them for cell membranes to be healthy.It may be somewhat premature, but for those of you asking about supplements to boost phosphatidyl-choline:
In my own personal case, a single dose of 300mg glycero-phospho-choline (GPC) caused temporary start-up effects of headache, weakness, worsened brain fog, worsened light/sound sensitivity, depression/irritability, preceded by a brief burst of energy and appetite loss.
Eventually these start-up effects faded and I was able to tolerate two daily doses of 300mg GPC without any problems. For what it's worth...
NT Factor EnergyLipids (the product linked above) is soy lecithin extract. The ingredient label says so.It contains phosphatidyl ethanolamine and the other constituents of membranes, in the correct ratios, without having to convert, which can be a problem for some people. A tub lasts me quite a while, even taking a higher dose, And I think it's better than soy lecithin.
If you have too much choline. Most ME/CFS patients tend to be short of acetylcholine.
I eat salmon about once a week, maybe twice, and my EPA and DHA are always well into the normal to high normal level. I'm usually short of the alpha linoleic acid which is in flax seeds and need to supplement that
It's necessary to supplement the others, too.
NT FactorBut where to get them?
https://www.clinicaleducation.org/r...-replacement-therapylrt-is-key-to-our-health/Why is there dysregulation of phospholipid metabolism in the first place ? Is it a consequence of mitochondrial dysfunction?
Wow. Confirming Leslie Simpson's & Ron Davis's research on RBC deformity in ME/CFS. Maybe should be a seperate thread.Meanwhile, Dr. Been discusses cell deformity in the context of LHS and a new method of its detection. Could come down to the same cell membrane pathology.
Α good question would be : Why is there dysregulation of phospholipid metabolism in the first place ? Is it a consequence of mitochondrial dysfunction?